24 DRUG DISCOVERY AND DEVELOPMENT
Fig. 1. Sleep apnea is associated with increased risk of cardiovascular disease including hypertension, heart failure and stroke.
Improving respiratory parameters in obstructive sleep apnea patients
Exploratory clinical study carried out with AMPAKINE compound, CX1739 in subjects with sleep apnea.
Étude clinique exploratoire réalisée avec un composé d’AMPAKINE, le CX1739, chez des sujets souffrant d’apnée du sommeil.
Mit AMPAKINE-Mischung durchgeführte klinische Forschungsstudien, CX1739 bei Subjekten mit Schlafapnoe.
www.scientistlive.com S
leep apnea is a sleep disorder characterised by abnormal pauses in breathing or
instances of abnormally low breathing, during sleep. Each pause in breathing, called an apnea, can last from a few seconds to minutes, and may occur many times per hour. Sleep apnea is typically diagnosed with an overnight sleep test called a polysomnogram. Tere are three forms of sleep apnea: central (CSA), obstructive (OSA), and complex or mixed sleep apnea.
Sleep apnea is associated with increased risk of cardiovascular disease including hypertension,
heart failure and stroke, and with increased risk of daytime sleepiness and auto vehicle fatalities. Te current standard of care for sleep apnea patients is treatment of the disease using a variation of a continuous positive airway pressure device (CPAP), which has been shown to be effective in reducing the apnea-hypopnea index in sleep apnea patients. However, the overall clinical benefit of CPAP is limited by relatively poor patient compliance rates reported for OSA patients. Despite low rates of patient compliance, the global CPAP device market exceeded one billion dollars in 2007. Other less frequently
prescribed treatment options for OSA patients include surgery, dental appliances and sleep position training. Currently there are no FDA-approved drugs for the safe and effective treatment of sleep apnea.
Exploratory study Cortex Pharmaceuticals Inc announced top-line results from an exploratory clinical study with its AMPAKINE compound, CX1739 in subjects with sleep apnea. Te study enrolled 20 relatively healthy adults with moderate-to-severe obstructive sleep apnea, 16 of which were administered a single oral dose of CX1739 and four of
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44